NuVasive's Q3 Earnings Hit By COVID-19, Staff Shortage; Cuts FY21 Guidance
See more from Benzinga
Terns' Potential NASH Candidate Shows Potent Liver Target Engagement
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.